Sinopharm vaccine (06660.HK): Both Sinopharm and American biotech companies will start clinical trials for their mRNA-based herpes vaccines, with their humoral and cellular immune responses significantly higher than international benchmark products.

Wisdom Financial News App News, Ami Vaccine (06660.HK) announced that after the vaccine obtained approval from the Food and Drug Administration (FDA) in the United States to conduct clinical trials in March 2025, the group's mRNA belt-shaped herpes vaccine has recently received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration. The vaccine has been approved in both China and the United States, fully verifying the strong strength of the group's mRNA technology platform.